Soleno Therapeutics

Contributing Author

Recent Articles by Soleno Therapeutics

Oct-21	Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET SLNO GlobeNewswire
Oct-13	Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors SLNO GlobeNewswire
Aug-27	Soleno Therapeutics to Participate in Upcoming September Conferences SLNO GlobeNewswire
Aug-06	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results SLNO GlobeNewswire
Jul-28	Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET SLNO GlobeNewswire
Jul-10	Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock SLNO GlobeNewswire
Jul-10	Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock SLNO GlobeNewswire
Jul-10	Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 SLNO GlobeNewswire
Jul-01	Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 SLNO GlobeNewswire
Jun-25	Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference SLNO GlobeNewswire
Jun-20	Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference SLNO GlobeNewswire
May-22	Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome SLNO GlobeNewswire
May-21	Soleno Therapeutics to Participate in Upcoming June Conferences SLNO GlobeNewswire
May-20	Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome SLNO GlobeNewswire
May-15	Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 SLNO GlobeNewswire
May-13	Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 SLNO GlobeNewswire
May-08	Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025 SLNO GlobeNewswire
May-07	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results SLNO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.